Statement Of Changes In Equity [Abstract]

ABIONYX Pharma - Filing #2821124

Concept	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	—	176 730 EUR	1 232 EUR	—	30,000 EUR	39,000 EUR	11 797 EUR	170 322 EUR	—	6 629 EUR	—	—	—	11 699 EUR	25,000 EUR	92,000 EUR	—	168 621 EUR	6 666 EUR	174 818 EUR	—	1 097 EUR	—	—	11 601 EUR	25,000 EUR	947,000 EUR	167 832 EUR	176 595 EUR	3 838 EUR	78,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	1 886 EUR	—	—	1 886 EUR	—	—	—	—	—	—	—	—	—	—	—	—	1 849 EUR	—	—	—	1 849 EUR	—	—	—	—	—	—	—	—	—	—
Comprehensive income	1 891 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 849 EUR	—	—	—	—	—	—	—	—	—	—
Issue of equity	1 837 EUR	—	—	—	—	—	—	—	—	—	135,000 EUR	1 701 EUR	—	—	—	—	—	—	—	—	939,000 EUR	—	150,000 EUR	789,000 EUR	—	—	—	—	—	—	—
Increase (decrease) through treasury share transactions, equity	26,000 EUR	—	—	26,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	72,000 EUR	—	—	—	72,000 EUR	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	98,000 EUR	—	—	—	—	—	—	—	98,000 EUR	—	—	—	98,000 EUR	—	—	—	—	—	—	—	98,000 EUR	—	—	—	—	—	—	—	—	—	—